www.raisethevolumeoc.com Open in urlscan Pro
147.182.180.75  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Introduction
 * What are biomarkers?
 * Role of biomarkers
 * Biomarkers in OC
 * How testing works


RAISE THE VOLUME
ON OVARIAN CANCER

It's time to amplify the message that biomarker testing can be an important
first step toward understanding treatment options for people with ovarian
cancer.1

LEARN MORE



SHARE THIS PAGE TO TURN UP THE IMPACT AND LET OTHERS KNOW ABOUT BIOMARKER
TESTING IN OVARIAN CANCER.

COPY SHAREABLE LINK

Share on social




WHAT ARE BIOMARKERS?1

Biomarkers are genes or proteins found in blood, other body fluids, or tissues.
They help doctors check if the body is functioning properly, or if there might
be signs of illness. Doctors use biomarkers to:

MAKE A DIAGNOSIS

Some biomarkers can help doctors figure out if a person has a certain disease.

UNDERSTAND SOMEONE’S DISEASE BETTER

Other biomarkers give doctors an idea about how a disease might change over
time.

FIGURE OUT WHAT TREATMENTS COULD HELP

Certain biomarkers help doctors know if a treatment may be appropriate for a
patient.

KEEP TRACK OF A DISEASE

Some biomarkers help doctors monitor how a disease is doing or if a treatment is
working.

TELL IF SOMEONE IS MORE SUSCEPTIBLE TO A DISEASE

There are some biomarkers that can help doctors predict if a person has a higher
risk of getting a disease.


THE ROLE OF BIOMARKERS IN THE OVARIAN CANCER TREATMENT JOURNEY

Biomarkers can help doctors understand how well certain cancer treatments could
work. These treatments include targeted therapies and immunotherapies, which may
only be effective if specific biomarkers are present. Testing for these
biomarkers may help patients and doctors make better decisions about which
treatment could be right.1

By knowing about and advocating for biomarker testing, people with ovarian
cancer can take a more active role in their ovarian cancer journey and make sure
they get the most appropriate treatment for them.


COMMON BIOMARKERS IN OVARIAN CANCER


BRAF2

(B-Raf proto-oncogene, serine/threonine kinase)

Knowing if someone has a mutation in this gene can help doctors understand if a
patient might be eligible for a specific medicine.


BRCA1/22,3

(BReast CAncer genes 1 and 2)

Mutations in BRCA1/2 genes can help doctors know if someone is more likely to
get ovarian cancer because of genetics and determine which treatment could be
right for them.


CA-1252,4

(Cancer antigen 125)

CA-125 can help doctors tell how well a treatment is working and see if
someone’s cancer has gotten worse or come back.


FRΑ OR FOLR15

(Folate receptor alpha or folate receptor 1)

FRα is a biomarker that helps doctors know whether a type of targeted treatment
might be effective.


HER22

(Human epidermal growth factor receptor 2)

Knowing someone’s HER2 status can determine whether a type of targeted treatment
might be effective.


HRD STATUS2

(Homologous recombination deficiency)

If someone doesn't have BRCA1/2 mutations, HRD status can help doctors know if a
certain targeted therapy might be appropriate.


MMR2

(Mismatch repair)

Knowing someone’s MMR status can tell doctors if they could be appropriate for a
type of immunotherapy.


MSI2

(Microsatellite instability)

Someone’s MSI status can help doctors know if they are eligible for a type of
immunotherapy.


NTRK2

(Neurotrophic tyrosine receptor kinase)

If doctors find a change in this gene, their patient may be a good fit for a
certain kind of targeted treatment.


RET2

(Rearranged during transfection)

Finding out if someone has a change in this gene can help doctors decide if a
patient might be able to receive a type of targeted treatment.


TMB2

(Tumor mutational burden)

Having this information can help doctors tell if a type of immunotherapy might
be a good fit for a patient.


HOW BIOMARKER TESTING WORKS1

SAMPLE COLLECTION

Doctors may collect samples of cancer cells through various methods such as a
biopsy, during which a small piece of the tumor is removed, or surgery. Samples
might also be taken from blood, skin, or saliva.

LABORATORY ANALYSIS

The collected samples are analyzed in a specialized lab where scientists look
for the presence or levels of specific relevant biomarkers.

TREATMENT OPTIONS

Based on the reports from the testing, healthcare teams can better assess the
characteristics of the tumor. They then work with patients to select the
treatment strategy that will be most likely to be effective in combating the
cancer.


KNOWING BIOMARKERS
PROVIDES OPTIONS1

When diagnosed with ovarian cancer, it's important to discuss biomarker testing.
Being aware of biomarker status can open doors to different treatment options
and help patients and their doctors figure out the best path forward for them.




SHARE THIS PAGE AND RAISE THE VOLUME ON OVARIAN CANCER AWARENESS MONTH TO HELP
OTHERS LEARN ABOUT THE IMPORTANCE OF BIOMARKER TESTING.

COPY SHAREABLE LINK

Share on social



References:
1. Biomarker tests and cancer treatment. American Cancer Society. Updated
September 21, 2022. Accessed August 28, 2024.
https://www.cancer.org/cancer/diagnosis-staging/tests/biomarker-tests.html
2. Referenced with permission from the NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian Tube Cancer
and Primary Peritoneal Cancer v3.2024. © National Comprehensive Cancer Network,
Inc. 2024. All rights reserved. Accessed August 28, 2024. To view the most
recent and complete version of the guideline, go online to NCCN.org. NCCN makes
no warranties of any kind whatsoever regarding their content, use or application
and disclaims any responsibility for their application or use in any way.
3. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer.
Mol Oncol. 2009;3(2):138-150. doi:10.1016/j.molonc.2009.02.001
4. Society of Gynecologic Oncology. Use of CA125 for monitoring ovarian cancer.
June 1, 2009. Accessed August 28, 2024.
https://www.sgo.org/resources/use-of-ca125-for-monitoring-ovarian-cancer/
5. Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab
soravtansine in patients with platinum-resistant ovarian cancer with high folate
receptor alpha expression: results from the SORAYA study. J Clin Oncol.
2023;41(13):2436-2445. doi:10.1200/JCO.22.01900

© 2024 AbbVie. All rights reserved. US-UNB-2400025v1.0 09/2024
ImmunoGen is now part of AbbVie. AbbVie and their respective logos are
trademarks or registered trademarks of AbbVie.